Key terms
About GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GOVX news
Mar 07
8:15am ET
Noble Financial Reaffirms Their Buy Rating on GeoVax Labs (GOVX)
Mar 06
9:02am ET
GeoVax Labs achieves milestone in transition to validated manufacturing system
Mar 01
4:11pm ET
GeoVax Labs files $100M mixed securities shelf
Mar 01
8:10am ET
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)
Feb 29
4:08pm ET
GeoVax Labs reports Q4 EPS (14.29) vs ($12.39) last year
Feb 16
4:13pm ET
GeoVax Labs Avoids Nasdaq Delisting with Reverse Stock Split
Feb 06
9:04am ET
GeoVax Labs reports interim data from Phase 2 trial of GEO-CM04S1
Jan 30
7:50pm ET
Geovax Labs Inc trading halted, news pending
Jan 08
9:10am ET
GeoVax Labs appoints Pipas as Executive Medical Director, Oncology
Jan 04
9:08am ET
GeoVax Labs announces Gedeptin patient enrollment closure for Phase 1/2 trial
Jan 03
9:02am ET
GeoVax Labs announces issuance of Malaria vaccine patent
Jan 02
4:12pm ET
GeoVax Labs files to sell 21.13M shares of common stock for holders
Dec 19
9:02am ET
GeoVax Labs expands rights under NIH COVID-19 license to include Mpox, smallpox
No recent news articles are available for GOVX
No recent press releases are available for GOVX
GOVX Financials
Key terms
Ad Feedback
GOVX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GOVX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range